Avecho Biotechnology’s TPM®‑enhanced CBD capsule for chronic insomnia advances in Phase III after an independent Data Monitoring Board recommends continuing without expanding enrollment, reinforcing trial design, safety, and commercial potential.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Avecho Biotechnology has cleared a major milestone in the development of its TPM®-enhanced cannabidiol (CBD) soft-gel capsule for chronic insomnia after an independent Data Monitoring Board (DMB) recommended continuing the pivotal Phase III trial without increasing the planned sample size. The decision supports the study’s statistical assumptions, reinforces the product’s safety profile, and reduces development risk as the program moves toward completion.
The recommendation follows an interim analysis of 244 participants enrolled in the randomized, double-blind, placebo-controlled Phase III study (NCT05840822). Participants received nightly doses of either 75 mg CBD, 150 mg CBD, or placebo for eight weeks. The DMB, the only group with access to unblinded trial data, unanimously concluded that the study met its predefined interim criteria and should continue with the originally planned enrollment of 519 participants.
TPM® Technology Targets Improved Oral CBD Delivery
Avecho’s investigational therapy combines cannabidiol with its proprietary Tocopheryl Phosphate Mixture (TPM®), a vitamin E-derived drug delivery platform that improves the solubility and oral absorption of compounds with poor bioavailability. The company is developing the formulation as a potential pharmaceutical treatment for chronic insomnia.
Insomnia affects an estimated 10% to 15% of adults as a chronic condition and often leads to impaired daytime function, reduced productivity, and poorer quality of life. Current prescription sleep medicines may cause next-day sedation, cognitive impairment, dependence, or overdose risk, highlighting the need for safer long-term treatment options.
Interim Analysis Supports Trial Design and Safety
The interim review found that treatment effect and data variability remained consistent with the assumptions used to power the study. As a result, the DMB did not recommend expanding enrollment beyond the planned 519 participants, an outcome that supports the robustness of the original trial design.
Safety findings also remained favorable. No serious adverse events were reported among the 244 participants evaluated during the interim analysis. While efficacy data remain blinded until study completion, the successful interim review allows recruitment to proceed into the second cohort without protocol changes.
Chief Executive Officer Dr. Paul Gavin said the recommendation validates the study’s rigorous design, including its dual primary endpoints, strict eligibility criteria, and measures to minimize placebo effects.
Although investigators remain blinded to treatment allocation, he said the interim outcome increases confidence that the CBD capsule could provide a clinically meaningful treatment option for insomnia.
Commercial Strategy Expands Beyond Australia
Avecho licensed Australian commercial rights to the CBD TPM capsule to Sandoz in 2025 under an agreement that included a US$3 million upfront payment, potential milestone payments of up to US$16 million, and tiered royalties on future sales. The positive interim review is expected to strengthen licensing discussions for territories outside Australia and support engagement with the U.S. Food and Drug Administration and other international regulators on future development pathways.
The company has already identified additional clinical sites to accelerate recruitment of the remaining participants and expects enrollment to be completed within approximately 12 months. If successful, the Phase III trial will support a regulatory submission to Australia’s Therapeutic Goods Administration, potentially positioning the CBD TPM capsule as one of the first approved over-the-counter pharmaceutical cannabidiol treatments for insomnia in the country.
Reference
Positive Interim Analysis Advances Avecho Phase III Insomnia Program
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.